-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure Medical Expects To Report Higher Q4 Sales In North America Compared To Last Year

Benzinga·12/17/2025 13:46:09
Listen to the news

ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States

CAESAREA, Israel, Dec. 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, is expecting to report a significant increase in fourth quarter sales in North America compared to the same period last year. Based on currently available preliminary information, the increase in sales would represent record North American sales levels for the Company. The Company is experiencing a surge of interest for the ProSense® console and its disposable cryoprobes following the U.S. Food and Drug Administration's ("FDA") marketing authorization of ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above in October 2025.